At what age can patients start receiving Heplisav-B, the Hepatitis B vaccine?

Heplisav-B, the Hepatitis B vaccine, has been approved for use in individuals aged 18 years and older. This vaccine is designed to provide protection against Hepatitis B virus infection with a two-dose schedule, each dose given at least 4 weeks apart. The rationale for specifying this age group is based on clinical trials demonstrating the safety and efficacy of the vaccine in adults. Vaccination in this age group is essential as Hepatitis B can lead to serious health issues like liver disease and liver cancer, and vaccinating those starting at 18 ensures that young adults are protected before potentially high-risk behaviors or exposure situations arise. Therefore, the correct answer aligns with the FDA recommendations and clinical guidelines for the administration of Heplisav-B.